Archives

Use the basic search or click on advanced for more search options.

Advanced Search Basic Search Advanced Search

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-10-16
    E.g., 2018-10-16

Archive Search

Pages

284 results
11:18 AM, Sep 28, 2018  |  BC Week In Review | Company News  |  Deals

Everest adds another antibiotic to pipeline through VenatoRx deal

bacterial pneumonia (HABP/VABP). VNRX-5133 is an IV broad-spectrum beta lactamase (LACTB) inhibitor; cefepime is a cephalosporin antibiotic
3:05 PM, Sep 25, 2018  |  BC Extra | Company News

Everest adds another antibiotic to pipeline through VenatoRx deal

bacterial pneumonia (HABP/VABP). VNRX-5133 is an IV broad-spectrum beta lactamase (LACTB) inhibitor; cefepime is a cephalosporin antibiotic
6:06 AM, Sep 14, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Merck's Zerbaxa non-inferior to meropenem in Phase III for bacterial pneumonia

infections (cIAIs) and complicated urinary tract infections (cUTIs), including pyelonephritis. The combination of ceftolozane, a cephalosporin antibiotic
Product: Zerbaxa ceftolozane/tazobactam  Business: Infectious  Molecular target: AmpC beta lactamase  Description: Combination of ceftolozane, a cephalosporin antibiotic
12:25 PM, Apr 27, 2018  |  BC Week In Review | Clinical News  |  Preclinical Results

VenatoRx reports preclinical data for VNRX-5133 plus cefepime

from a mouse model of cephalosporin-resistant Klebsiella pneumoniae lung infection showing that VNRX-5133 plus the cephalosporin antibiotic
12:04 PM, Oct 27, 2017  |  BC Week In Review | Financial News  |  Other Financial News

China Resources planning China pharma fund

The China Resources Pharmaceutical Equity Investment Fund Management (Shantou) Company Ltd. subsidiary of drug distribution company China Resources Pharmaceutical Group Ltd. (HKSE:3320) proposed to raise RMB2,500 million ($376.8 million) in its China Resources Pharmaceutical Industrial...
11:55 AM, Oct 27, 2017  |  BC Week In Review | Company News  |  Deals

NIH, Geom to conduct Phase I of GT-1

The double-blind, placebo-controlled, dose-escalation study will evaluate safety and pharmacokinetics in healthy volunteers. GT-1, a cephalosporin antibiotic
12:31 PM, Oct 26, 2017  |  BC Extra | Financial News

China Resources planning China pharma fund

The China Resources Pharmaceutical Equity Investment Fund Management (Shantou) Company Ltd. subsidiary of drug distribution company China Resources Pharmaceutical Group Ltd. (HKSE:3320) proposed to raise RMB2,500 million ($376.8 million) in its China Resources Pharmaceutical Industrial...
2:40 PM, Sep 29, 2017  |  BC Week In Review | Company News  |  Deals

Basilea grants China Resources Holdings rights to Zevtera in China

hospital-acquired pneumonia (HAP), excluding ventilator-associated pneumonia (VAP). Zevtera is a prodrug of ceftobiprole, a broad-spectrum cephalosporin antibiotic
12:11 PM, Sep 08, 2017  |  BioCentury | Finance

Antibiotic engine

C LACTB in preclinical development. The company is developing ETX0282 in combination with the generic cephalosporin antibiotic
1:04 PM, Nov 11, 2016  |  BC Week In Review | Company News  |  Deals

Eli Lilly, Eddingpharm deal

introduce 10 new drugs to the China market over the next decade. Ceclor is a cephalosporin antibiotic

Pages